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Introduction: The incidence of breast cancer diagnosed during pregnancy is expected to increase as more women
delay childbearing in the United States. Treatment of cancer in pregnant women requires prudent judgment to
balance the benefit to the cancer patient and the risks to the fetus. Prospective data on the outcomes of children
exposed to chemotherapy in utero are limited for the breast cancer population.
Methods: Between 1992 and 2010, 81 pregnant patients with breast cancer were treated in a single-arm, institutional
review board–approved study with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) in the adjuvant or
neoadjuvant setting. Labor and delivery records were reviewed for each patient and neonate. In addition, the parents
or guardians were surveyed regarding the health outcomes of the children exposed to chemotherapy in utero.
Results: In total, 78% of the women (or next of kin) answered a follow-up survey. At a median age of 7 years, most of
the children exposed to chemotherapy in utero were growing normally without any significant exposure-related toxicity
or health problems. Three children were born with congenital abnormalities: one each with Down syndrome, ureteral
reflux or clubfoot. The rate of congenital abnormalities in the cohort was similar to the national average of 3%.
Conclusions: During the second and third trimesters, pregnant women with breast cancer can be treated with FAC
safely without concerns for serious complications or short-term health concerns for their offspring who are exposed to
chemotherapy in utero. Continued long-term follow-up of the children in this cohort is required.
Trial registration: ClinicalTrials.gov Identifier: NCT00510367. Other Study ID numbers: ID01-193, NCI-2012-01578.
Registration date: 31 July 2007.Introduction
Breast cancer is the most common malignancy associated
with pregnancy; however, only 0.2% to 2.9% of all breast
cancers occur during pregnancy [1,2]. As women are
delaying childbearing, the incidence of breast cancer dur-
ing pregnancy is increasing [3-5]. Management of breast
cancer during pregnancy requires an intricate balance be-
tween using multiple modalities to effectively treat the
mother and minimizing the potential toxicities for the
fetus [6]. The factors that must be considered include the
breast cancer subtype, the extent of disease at the time of
diagnosis, the mother’s general health, the proposed* Correspondence: jlitton@mdanderson.org
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unless otherwise stated.treatment plan, the health of the fetus and the gestational
age at diagnosis [7].
Compared with breast cancer in nonpregnant patients,
breast cancer in pregnant women is often diagnosed at a
more advanced stage and is more likely to present with a
large tumor size, high nuclear grade, lymph node involve-
ment, lymphovascular invasion and hormone receptor–
negative status [8]. The treatment goals for pregnant
patients are the same as those for nonpregnant patients:
to achieve local disease control and prevent systemic re-
currences [9]. Pregnancy itself does not appear to be asso-
ciated with worse breast cancer outcomes [10,11]. With
appropriate local and systemic therapy, women treated
with chemotherapy during pregnancy have clinical out-
comes that are no worse than those of nonpregnant pa-
tients matched for age and breast cancer stage [12].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been based upon case reports, retrospective data, case
series and anecdotal evidence [13]. In selected cases, sur-
gery may be the first therapy offered. Chemotherapy, given
either neoadjuvantly or adjuvantly, is often required be-
cause most pregnant patients are young and present with
biologically aggressive and/or large locally advanced tu-
mors. When radiation therapy for breast cancer is needed,
it is deferred until after childbirth to avoid radiation ex-
posure to the fetus.
Information on the effects of antineoplastic drugs admin-
istered during pregnancy has been focused largely on fetal
abnormalities (for example, spontaneous abortion, malfor-
mations, fetal intrauterine growth retardation, fetal death).
The period of pregnancy during which the fetus is exposed
to chemotherapy appears to be critical, as the highest risk
for fetal malformation occurs during fetal organogenesis in
the first trimester [14]. When chemotherapy is adminis-
tered during the second and third trimesters, the reported
fetal malformation rates range from 1.3% to 3.8%, which
are similar to the rate reported for the general population
[15-17]. Anthracycline-based chemotherapy can be admin-
istered safely during the second and third trimesters
[18,19]. There are also data accumulating that support the
use of taxanes during pregnancy [20,21]. However, trastu-
zumab and endocrine therapy are reserved until after
childbirth because of the risks of fetal complications, even
when given in the second and third trimesters [16].
Although increasing evidence showing the safety and
efficacy of treatment with chemotherapy for breast can-
cer in the second and third trimesters has emerged, the
concurrent diagnosis of breast cancer and pregnancy re-
mains a clinical and ethical challenge for the oncologist,
obstetrician, pediatrician and patient. Limited data are
available regarding the long-term outcomes of children
exposed to chemotherapy in utero, and there are
currently no specific guidelines for monitoring such
children. More data about the long-term effects of ges-
tational chemotherapy exposure are needed to guide
pediatricians and other health care providers as they
continue to care for children with such exposure. At
the University of Texas MD Anderson Cancer Center,
women with breast cancer diagnosed during pregnancy
have received the same systemic chemotherapy regi-
men—5-flurouracil, doxorubicin and cyclophospha-
mide (FAC)—in the second and third trimesters since
1992 [13]. In 2006, Hahn et al. reported on the initial
follow-up of children exposed to these drugs in utero
and found no significant short-term complications for
the majority of those children [18]. The objective of
this study was to provide an update 8 years after the
initial report on the acute neonatal complications and
expand on the postneonatal outcomes of this cohort of
children exposed to chemotherapy in utero.Methods
Between 1992 and 2010, 81 patients who provided in-
formed consent and met the eligibility criteria for a pro-
spective, institutional review board (IRB)–approved trial
at our institution were treated using a standardized
chemotherapy regimen during the second and third tri-
mesters of their pregnancy. The IRB at the University of
Texas MD Anderson Cancer Center provided approval
for this study. Patients signed an IRB-approved informed
consent to be eligible for the study. No separate ethics
committee approved this study outside of the institu-
tional review board. All enrolled patients were treated in
compliance with the Declaration of Helsinki. The pa-
tients received outpatient combination chemotherapy
(FAC) with cyclophosphamide (500 mg/m2 intravenously
on day 1), doxorubicin (50 mg/m2 by continuous infusion
over 72 hours) and two bolus doses of 5-fluorouracil (500
mg/m2 intravenously on days 1 and 4) [18]. Each cycle
was given every 21 to 28 days, and therapy lasted through
gestational week 35. Other standard systemic therapies,
such as trastuzumab and endocrine therapy with tamoxi-
fen, were given after childbirth. Outcomes of the women
and short-term outcomes of the children exposed in utero
have been reported previously (n = 57) [13,18].
As part of their participation in the registry trial for
the treatment of breast cancer during pregnancy, the
participants also provided consent for obtaining delivery
records and subsequent questionnaires that provided
data for this analysis. Labor and delivery records were
obtained, and relevant data were recorded and updated
in a prospective manner. A health survey/questionnaire
(Table 1) was sent to the parents or guardians of the
children who were exposed to chemotherapy in utero to
evaluate immediate and long-term outcomes. The survey
was divided into two portions: neonatal outcomes and
postneonatal outcomes. The survey questions covered is-
sues related to delivery, puberty, reproductive capacity
and overall health concerns. The survey was added to
the study protocol in 2001, and the resultant data were
collected from 2001 through 2005. The survey was sent
out a second time in 2010 in an effort to capture as
much data as possible. The data are included in this art-
icle. Descriptive statistics were used to report the results.
Results
Of the 81 participants, 63 patients or their next of kin
(78%) answered at least some portion of the survey re-
garding the child exposed to chemotherapy in utero. Of
the surveys not accounted for, seven participants were
lost to follow-up. The reasons for inadequate follow-up
included death of study participant, a preference not to
respond or the inability to identify next of kin. Eleven
participants were enrolled in the study after the second
round of surveys was mailed in 2010. These participants
Table 1 Health questionnaire
Questionnaire items
Delivery and current health status
1 Delivery statistics: weight, weeks gestation, C-section or vaginal
delivery
2 Did your child have any medical problems at the time of delivery
such as having fever, needing oxygen, or being admitted to a
special care unit, such as intensive care?
3 Did your child have any medical problems in the first month
after birth after being discharged home after delivery?
4 Do you consider your child to be healthy?
5 Does your child have any of the following:
Breathing problems such as asthma
Heart problems such as a heart murmur
Stomach or other gastrointestinal problems such as heartburn
Bone/skeletal problems such as arthritis
Urinary problems (kidney or bladder problems)
Neurological problems (numbness, weakness)




6 If in school, has your child had any difficulties in school such as
requiring smaller class size, extra tutoring or one-on-one teaching?
7 Has your child started to have any developmental changes related
to puberty?
8 Has your child become pregnant or fathered a child?
9 Has your child tried to conceive, but had difficulty?
Concerns about cancer and parenthood
This section detailed the number of previous pregnancies at time
of diagnosis, wishes for future pregnancies, Reproductive Concerns
Scale and questions related to how pervasive the thoughts of cancer
are in day-to-day life.
Table 2 Delivery outcomes for children exposed to
chemotherapy in utero, overall
Delivery outcome Data
Mean gestational age at delivery, wk 37 (29 to 41)
Mean birth weight, kg 2.9 (1.3 to 3.9)
Type of delivery, n (%)
Cesarean section 27 (33.3)
Vaginal 54 (66.7)
Chemotherapy exposure, n (%)
>4 cycles of FACa 70 (86.0)
≤3 cycles of FAC 5 (6.0)
Unknown number of cycles 6 (7.0)
aFAC, 5-Fluorouracil, doxorubicin, and cyclophosphamide.
Table 3 Delivery outcomes for children exposed to
chemotherapy in utero, preterm
Delivery outcome Result, n
Preterm births (<37 wk) 28
Late preterm (32 to 36 wk) 27
Early preterm (<32 wk) 1
Cesarean section delivery 11
Vaginal delivery 17
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labor and delivery data, as these data were available.
Eighty-one children were born after exposure to vary-
ing numbers of anthracycline-based chemotherapies in
utero. Among the cohort, there were a total of 328 cy-
cles of FAC administered (mean = 4.2 cycles) (N = 81).
Eighty-six percent had exposure to at least four cycles
of anthracycline-based chemotherapy. Delivery data and
neonatal complications are shown in Tables 2, 3 and 4,
respectively. The mean gestational age at delivery was 37
weeks (range, 29 to 41 weeks). The mean birth weight
overall was 2.9 kg (range, 1.4 to 3.9 kg). Of the patients
with information available regarding delivery, 33% were
delivered by cesarean section, while 67% underwent nor-
mal vaginal delivery.
Twenty-eight children were delivered preterm, defined
as prior to 37 weeks’ gestation. Of these, one child was
delivered at 29 weeks, weighing 1.39 kg and requiring aprolonged neonatal intensive care unit stay lasting 2
months. Another child with exposure to one cycle of
anthracycline-based chemotherapy in utero was born at
32 weeks with a weight of 3.29 kg and required supple-
mental oxygen at the time of delivery. The remaining 26
preterm births occurred during gestational weeks 33 to
36. Among the preterm births, the mean birth weight
(2.8 kg) and the mean number of chemotherapy cycles ex-
posed to in utero (four cycles) were similar to the those in
the general cohort. The majority of the preterm births
were spontaneous vaginal deliveries (n = 27; 63%), without
complications. Eleven preterm births (40%) occurred by
cesarean section, and two of the mothers required emer-
gent procedures. One of the emergent procedures was as-
sociated with maternal heart problems and fetal distress,
and the other was a breach delivery.
At delivery, 63 patients had data evaluable for neonatal
complications. The following complications were noted:
17% (n = 11) required extra oxygen, 2% (n = 1) had sub-
arachnoid hemorrhage, 3% (n = 2) had hypoglycemia and
5% (n = 3) had jaundice (Table 4). Of the 63 patients, 38
had been exposed to four or more cycles of chemotherapy
in utero, and the majority (65%) did not have any neonatal
complications documented. One child with six cycles of in
utero chemotherapy exposure was born with poor tone,
which resolved soon after birth (not shown in Table 4).
Table 4 displays the neonatal complications documented
Table 4 Neonatal complications of children exposed to chemotherapy in utero
Complication n (%) ≥4 cycles of anthracycline-based
in utero chemotherapy exposure, n
<4 cycles of anthracycline-based






at delivery (N = 63a)
21 (33) 13 8 14 7
Breathing difficulties 11 (17) 9 2 7 4
Subarachnoid hemorrhage 1 (2) 1 0 1 –
Jaundice 3 (5) 2 1 2 1
Low heart rate 2 (3) 1 1 1 1
Hypoglycemia 2 (3) 0 2 1 1
Abnormal temperature 2 (3) 2 0 1 1
NICU/hospitalizations (N = 63a) 9 (14) 5 4 4 5
Prolonged NICU stayb (>1 mo) 2 (3) 0 2 2c –
Temporary hospital or
NICU stay (≤14 days)
7 (11) 5 2 2 5
aInformation on complications was available for 63 births. bThe reason for prolonged neonatal intensive care unit (NICU) stay was prematurity. cOne child had a
2-month stay due to being born at 29 weeks. The other child was delivered at 35 weeks.
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more cycles of in utero chemotherapy and according to
whether the delivery was preterm or at term. Of the 21 pa-
tients with neonatal complications, 62% were exposed to
at least four cycles of chemotherapy in utero. Seventeen
percent of neonates had breathing difficulties at birth.
Among the preterm neonates with respiratory difficulty,
almost all the cases were due to premature lung develop-
ment. These neonates required at most supplemental oxy-
gen by nasal cannula. One preterm neonate did have
documented respiratory distress syndrome. Of the term
neonates, one had just nasal flaring and one had transient
tachypnea requiring oxygen for 24 hours. Another term
neonate had nuchal cord and required cardio-pulmonary
resuscitation because of this and one other had labored
breathing with supplemental oxygen and therefore was
intubated but subsequently weaned off within 8 hours.
Eighty-two percent of neonates with breathing difficul-
ties and fifty-six percent requiring temporary or pro-
longed hospital stays had been exposed to four or more
cycles of chemotherapy in utero. Of the entire cohort
(N = 81), congenital abnormalities remained the same as
reported in 2006 [18]: one child was born with Down
syndrome, one with clubfoot and one with ureteral re-
flux (hydronephrosis).
Postneonatal outcomes are given in Table 5, which
shows health conditions reported in the survey and the
prevalence of these conditions in the general popula-
tion. The median age of the children at the time of sur-
vey completion was 7 years (range, <1 to 21 years). Of
the 50 participants who responded to the portion of the
survey evaluating postneonatal outcomes, 13 (26%) were
between 13 and 22 years old. The remainder had chil-
dren who were school-aged (ages 3 to 12 years; n = 19)
or infants (0 2 years of age; n = 17). The majority ofsurvey responders considered their children to be healthy
overall, and only minor health issues were reported, as
noted in Table 5. Of note, 31 patients reported a health
issue, and 61% of these 31 patients had extensive in utero
chemotherapy exposure (four or more cycles). For each
data point of the health issues reported, the prevalence in
the general population has been noted in Table 5 as a ref-
erence for comparison as well as the number of those with
each health concern who have been exposed to four or
more cycles of anthracycline-based chemotherapy in
utero. Nineteen children were described as being healthy,
and 47% of these had in utero exposure to four or more
cycles of anthracycline-based chemotherapy. Twelve per-
cent of the survey responders indicated that their children
had developmental milestone delays. Three of these were
childhood language delays. There were no significant cog-
nitive abnormalities reported in the children. Of the 37
children who were reported to be enrolled in preschool
through college, four reported having any difficulties in
school. Three children, one of whom had recently gradu-
ated from college, were reported to have reading delays,
and one child in seventh grade was reported to have diffi-
culty with attention span. Eleven children had advanced
past the seventh grade, and the majority (90%; n= 10) re-
ported no difficulties. There was one child enrolled at the
time in a college bachelor’s degree program. Other health
problems reported by survey responders included 18 chil-
dren with allergies and/or eczema (36%), 5 with asthma
(10%), 1 with migraine headaches and 1 with absence sei-
zures. Only allergies and/or eczema occurred at a prevalence
higher than the general population reference rate. Sixty-
seven percent of those with allergies and/or eczema had
been exposed to more than four cycles of anthracycline-
based chemotherapy in utero, and four of the five chil-
dren who developed asthma also had more extensive
Table 5 Postneonatal outcomes of children exposed to chemotherapy in utero
Reported outcome n/N (%) ≥4 cycles of anthracycline-based in utero
chemotherapy exposure, n/N (%)
Population prevalence, % [reference]
Child considered healthy 49/50 (98) – –
Developmental milestone delays 6/50 (12) 2/6 (33) 10 [22]
Difficulties in schoola 4/37 (11) 3/4 (75) 6-11 [22]
Reported health concerns 31/50 (62) 19/31 (61) –
Allergies/eczema 18/50 (36) 12/18 (67) 11 to 25 [22]
Asthma/breathing 5/50 (10) 4/5 (80) 13 [22]
Vision 8/50 (16) 5/8 (63) 14 [22]
Heart murmurb 1/50 (2) – 1.3 [23]
“Lazy eye” 2/50 (4) 1/2 (50) 1.6 to 3.6 [24]
Absence seizuresc 1/50 (2) 1/1 (100) <1 [25]
ENTd 4/50 (8) 3/4 (75) HL, <1; ROM, 18 to 26d [26]
GERDe 2/50 (6) 2/2 (100) 5 to 67f [27]
aReading delay (n = 3) and difficulty with attention span (n = 1); data are for 37 school-aged children. bResolved by age 1 year. cPossibly hereditary. dEar, nose,
and throat (ENT) includes recurrent otitis media (ROM; n = 2), sinus problems (n = 1) and hearing deficit (HL; n = 1). eGastroesophageal reflux disease.
fVaries according to age.
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children diagnosed with asthma, three had been born pre-
term and had breathing difficulties secondary to prematurity
at birth. Ear, nose, and throat (ENT) issues were reported in
8% of children. One child was reported to have a hearing
deficit and had exposure to six cycles of chemotherapy in
utero. The other ENT concerns included sinus problems
and recurrent otitis media, with one of these individuals re-
quiring a myringotomy. The majority of survey respondents
informed us that their children had not experienced changes
related to puberty; only 24% (n = 12) of children had en-
countered pubertal changes. It is important to note, how-
ever, that only 13 children were of pubertal age (age 13 years
and older). The mean age of puberty onset was 11 years
(range, 10 to 13 years), and only one child was noted to have
precocious hair growth at age 4 years. There are not yet any
offspring of the children.
Discussion
Our data indicate that treating women with anthracycline-
based systemic chemotherapy for breast cancer during the
second and third trimesters of pregnancy can be adminis-
tered without significant impairment of the health of their
offspring at delivery or into childhood compared with chil-
dren in the general population. To date, limited data exist
regarding potential health concerns for children exposed
to chemotherapy in utero. Hahn et al. reported in 2006 on
the presentation, treatment and outcomes of the first 57
pregnant women treated according to study protocol. The
authors reported the outcomes of children who were ex-
posed to chemotherapy in utero; and they found the ma-
jority of the children to be healthy and without significant
developmental problems [18]. The German Breast Groupenrolled 413 pregnant women with early-stage breast can-
cer in a prospective registry study and found that the sta-
tistically insignificant increased incidence of low birth
weights and obstetrical complications observed was linked
to premature delivery rather than to in utero chemother-
apy exposure during the second and third trimesters [19].
Furthermore, Amant et al. investigated children who were
prenatally exposed to any maternal cancer staging and
treatment, including chemotherapy, and found no impair-
ment in the general health or growth of these children.
Specifically, there were no associations with increased cen-
tral nervous system, cardiac or auditory toxicity [28].
In the present study, we found that, at a median age of 7
years, children who were exposed to anthracycline-based
chemotherapy in utero were growing well, with no signifi-
cant toxic effects observed related to chemotherapy expos-
ure. There were three children born with congenital
abnormalities, which were Down syndrome, ureteral reflux
and clubfoot. The child with Down syndrome was born to
a 32-year-old woman. The rate of congenital abnormalities
in our population is similar to the US average rate of ap-
proximately 3% [15]. The chief long-term health concerns
were allergies and/or eczema, which occurred more com-
monly in the children in our study than currently reported
in the general population. The majority of patients report-
ing allergies and/or eczema were exposed to four or more
cycles of anthracycline-based chemotherapy in utero; how-
ever, this finding may be the result of generalized overre-
porting. There have been no significant delays reported in
puberty. To determine whether more extensive in utero
chemotherapy exposure translates to worse health out-
comes overall will require more prolonged follow-up and
a prospective study with more objective data. It is
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to receive four cycles of FAC in total, with perhaps less be-
ing given during the in utero period, depending on the
timing of the diagnosis of breast cancer during the preg-
nancy and the timing of the surgical intervention. Con-
tinuing to follow cohorts of children such as these, along
with multi-institutional and multinational collaborations,
are needed to further address these concerns for the chil-
dren, especially as they mature into adults.
Our results support previous efforts to evaluate whether
children of cancer patients encounter any late adverse
health effects due to in utero chemotherapy exposure. In
the 457 studies reviewed in the National Toxicology Pro-
gram monograph (2013) [29], 60% of the children exposed
to gestational chemotherapy had follow-up data available.
Normal growth and development were reported for all;
however, most of the children were not evaluated beyond
year 2 of life. Other investigators have performed longer-
term evaluations of children exposed to chemotherapy in
utero. The largest dataset to date consists of 84 pregnant
women who were treated for hematologic malignancies
and whose children and grandchildren (n = 12) partici-
pated in a study for follow-up of the long-term effects of
the treatment. At a median follow-up of 18.7 years, there
were no cases of leukemia and no long-term ill effects re-
lated to physical health, growth or development among
the children exposed to chemotherapy in utero or among
their offspring [30].
The main limitations of the present study include its small
sample size, subjective nature (via questionnaire) and short
follow-up period. The numbers of older and postpubertal
children are small. The outcomes of the exposed children
were assessed through a survey distributed to the children’s
parents or guardians. Although the response rate for this
study was satisfactory, we could not assess all eligible chil-
dren. Behavioral and emotional outcomes of the children
might be better addressed by a survey directed to the chil-
dren themselves. Although the survey form was written at a
low literacy level, the educational backgrounds of the re-
spondents may have varied and thus may have contributed
to the number of incomplete surveys. Additionally, it might
be effective to minimize free text and create a standardized
case report form [19] for data collection, which could be ex-
panded to capture data from other cohorts in centers across
the United Stataes. Furthermore, the results may have been
more reliably gained by using an objective format such as
pediatricians’ records or chart reviews as compared to ques-
tionnaires. It will be important to continue to follow these
patients in the future and obtain more objective data for
them, such as records from pediatric visits and hospitaliza-
tions. Additionally, the follow-up period was short, as the
median age of the children was 7 years. Continued follow-
up of this growing cohort is essential. It will be valuable to
note the incidence of chronic health conditions, cancer andfertility issues as the children enter puberty and adulthood
and of labor and/or delivery complications as the children in
the study have children of their own.
Conclusions
This cohort of children exposed to chemotherapy in utero
appeared to be doing well, with no trend to indicate a
higher rate of serious medical problems than that seen in
the general population. This is an important prospective
single-institution study of outcomes of children exposed
in utero to anthracycline-based chemotherapy for breast
cancer. Pregnant women and physicians can be reassured
that treating breast cancer during the second and third tri-
mesters with anthracycline-based chemotherapy does not
jeopardize the health outcomes of the developing fetus.
No specific recommendations regarding health monitor-
ing for these children outside of the recommendations for
the general population are supported by these data. Poten-
tial concerns may arise and will need to be followed in this
cohort as well as others. These concerns include future
childbirth and fertility issues as more offspring reach pu-
berty, as well as the cancer incidence in the population ex-
posed to chemotherapy in utero. Future exploration of
cognitive impairment, high school graduation rates and
college attendance rates, as well as continued long-term
follow-up of this and other cohorts, is needed to provide
more information to parents and pediatricians.
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